Edwards Lifesciences
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $1,354,400 | $1,385,900 | $1,598,200 | $1,534,100 |
Gross Profit | 1,092,800 | 1,088,100 | 1,214,000 | 1,177,200 |
EBITDA | 402,800 | 404,300 | 526,400 | 368,300 |
EBIT | 394,300 | 364,700 | 487,900 | 331,500 |
Net Income | 3,070,800 | 366,300 | 351,900 | 369,900 |
Net Change In Cash | 1,354,400 | 1,385,900 | 1,598,200 | 1,534,100 |
Free Cash Flow | 286,100 | -138,800 | 35,000 | |
Cash | 1,648,000 | 1,224,600 | 1,144,000 | |
Basic Shares | 598,100 | 604,300 | 604,100 | 606,900 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $6,004,800 | $5,382,400 | $5,232,500 | $4,386,300 |
Gross Profit | 4,625,000 | 4,302,000 | 3,983,600 | 3,305,700 |
EBITDA | 1,534,100 | 1,829,900 | 1,483,300 | 1,735,600 |
EBIT | 1,534,100 | 1,663,100 | 1,320,000 | 1,600,200 |
Net Income | 1,402,400 | 1,521,900 | 1,503,100 | 823,400 |
Net Change In Cash | 6,004,800 | 5,382,400 | 5,232,500 | 4,386,300 |
Cost of Revenue | -114,000 | -346,700 | 36,300 | |
Free Cash Flow | 629,500 | 953,400 | 1,402,300 | 647,000 |
Cash | 1,144,000 | 769,000 | 862,800 | 1,183,200 |
Basic Shares | 609,400 | 624,200 | 631,200 | 631,900 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $0.67 |
2024-06-30 | $0.70 |
2024-03-31 | $0.66 |
2023-12-31 | $0.64 |
